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ABSTRACT
Given the large number of children treated with
methylphenidate, it has become increasingly important to
evaluate the possible long-term consequences of
methylphenidate treatment. To assess whether the
reinforcing properties of drugs of abuse were altered in
adulthood, we administered methylphenidate daily from
postnatal days 11-20 and then measured preference for
morphine during early adulthood using conditioned place 
preference. The number of dopamine D2 receptors was
measured in each rat and the correlation between receptor
number and morphine preference was determined. Regardless
of sex or pretreatment group, rats exhibited morphine-
induced CPP as rats treated with the 5.0 mg/kg morphine had
significantly greater difference scores as compared to rats
treated with saline. D2 binding densities were not altered
by methylphenidate pretreatment or morphine exposure. This
evidence implies that preweanling rats exposed to
methylphenidate can alter drug-rewarded behavior and
enhance drug responsiveness in adulthood and suggests that
treating young children (e.g. preschool age) with
iii
methylphenidate may increase the risk of drug addiction
later in life.
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CHAPTER ONE
INTRODUCTION
Overview
In the United States, psychostimulant drugs [e.g., 
methylphenidate (Ritalin) and amphetamine (Dexedrine; 
Allderall) are the most commonly prescribed psychotropic
medications given to children (DEA Congressional Testimony, 
2000). Psychostimulant treatment is most commonly used for 
Attention Deficit Hyperactivity Disorder (ADHD), but it is
also the preferred treatment for narcolepsy and other
disorders (Wilens & Biederman, 1992) . It has been estimated
that as high as 15% of school-age children meet the DSM-IV 
diagnostic criteria for ADHD (Scahill & Schwab-Stone, 2000). 
The large majority of these children are prescribed
methylphenidate (Wilens & Biederman, 1992) . In fact, the 
number of children receiving methylphenidate treatment for
ADHD has doubled every five years since 1971 (Wilens &
Biederman, 1992). Given the large number of children 
treated with methylphenidate, it has become increasingly
important to evaluate the possible long-term consequences of 
methylphenidate treatment.
While most studies have concluded that methylphenidate 
has few long-term side effects (Borcherding, Keysor,
1
Rapoport, Elia, & Amass, 1990; Nolan & Gadow, 1997; Rappley, 
1997) , more recent research has found that early exposure to
methylphenidate can alter later behavior in adulthood.
(Andersen et al., 2002; Crawford et al., 2000) . For
instance, exposing adolescent rodents to methylphenidate
causes an increase in cocaine self-administration and
cocaine-induced conditioned place preference (Achat-Mendes
et al, Brandon, Marinelli, Baker, & White, 2001). Moreover,
similar results have been demonstrated in humans, as a
recent clinical study found that college students were more 
likely to abuse cocaine if they had previously received 
methylphenidate during childhood or adolescence (Schenk &
Davidson, 1998).
While the cause of this change in responsivity to 
cocaine is unknown, it is possible that changes in dopamine 
receptors may be involved. Repeated treatment with the 
psychostimulant methamphetamine during the preweanling 
period has resulted in a long-term reduction in the number 
of dopamine D2 receptors (Crawford et al.,2000a). Moreover, 
recent imaging studies in humans indicate a relationship 
between drug addiction and number of dopamine D2. receptors 
(Volkow, Fowler, Wang, & Goldstein, 2002) . Specifically,
the number of dopamine D2 receptors are predictive of the 
rewarding properties of psychostimulants. Subjects with
2
higher numbers of dopamine receptors did not find acute 
treatment with a psychostimulant pleasurable, while subjects 
with lower numbers of receptor sites did find the drug 
treatment pleasurable. Since methylphenidate and
methamphetamine share a similar mechanism of action
(Fumagalli, Gainetdinov, Wang, Valenzano, Miller, & Caron,
1999) , it is possible that early methylphenidate treatment 
may decrease dopamine binding sites and thus increase the 
probability of later drug abuse.
Proposal
It now appears that early methylphenidate treatment may 
have long-term effects on behavior. In particular, early 
methylphenidate treatment may increase later vulnerability 
to drugs of abuse. In order to assess whether the 
reinforcing properties of drugs of abuse are altered in 
adulthood, we will administer methylphenidate daily from 
postnatal day (PD) 11-20 and then measure preference for 
morphine during early adulthood (i.e., PD 60) using 
conditioned place preference. In addition, rats in this 
study will be sacrificed at the end of preference 
conditioning and their dorsal striata removed. The number 
of dopamine D2 receptors will be measured in each rat and
3
the correlation between receptor number and morphine
preference will be determined.
4
CHAPTER TWO
LITERATURE REVIEW
Dopamine Systems
Dopamine is an important catecholamine neurotransmitter
involved in the mediation of reward, motor behavior, and
memory. Dopamine synthesis begins with the amino acid 
tyrosine, which is converted to L-dihydroxyphenylalanine (L- 
DOPA) in the presence of the enzyme tyrosine hydroxylase 
(Siegel, Agranoff, Albers, Fisher, & Uhler, 1999). L-DOPA 
is then converted to dopamine by the enzyme DOPA
decarboxylase (or aromatic amino acid decarboxylase) (Siegel 
et al., 1999) . Conversion of tyrosine to L-DOPA, as well as 
L-DOPA to DA occurs in the cytosol (Elsworth' & Roth, 1997). 
Free dopamine is then pumped into vesicles by the vesicular 
monoamine transporter (VMAT). Dopamine is released by 
calcium-dependent exocytosis (Robitaille, Adler, & Charlton,
1990). During this process, an action potential at the axon 
terminal triggers the opening of voltage-gated calcium 
channels inducing calcium ion influx and vesicular release 
of dopamine (Robitaille, Adler, & Charlton, 1990) . Newly 
synthesized dopamine is preferentially released, although 
stored dopamine can be mobilized after repeated
stimulation. After release, dopamine is primarily
5
adenylyl cyclase activity, D2 receptors actually inhibit 
adenylyl cyclase activity (Baldessarini & Tarazi, 1996) . As 
more receptor subtypes were identified over the years (Dx 
through D5) , Clark and White (1987) classified the receptor 
subtypes into Di-like ( Dx and D5) and D2-like (D2, D3, and 
D4) families. As research continued, two distinct forms of 
the D2 receptor'became evident; D2(iong) and D2(short) • These D2 
receptor subtypes were found to differ by only a 29-amino 
acid insertion in the intracellular loop (Smith, Fetsko, & 
Wang, 2002). Clark and White (1987) devised their
nomenclature through an extensive review of studies using 
both dopamine agonists and antagonists.
Dopamine agonists, which compete for the same receptor,
cause the same effect as the endogenous neurotransmitter and 
stimulates the receptor. Typical Dx/D5 agonists include SKF 
38393, fenoldopam, and dihydrexidine (Gorelova & Yang,
2000). Although no compounds differentiate Dx and D5 
receptors, these receptors differ in other aspects. The 
most widely accepted difference between Dx and D5 receptors 
is that D5 receptors display a higher affinity for dopamine 
than do Dx receptors (Grandy et al., 1991; Sunahara et al.,
1991; Tiberi et al., 1991). This observation is in accord
with later research showing that D5 receptors have a
stronger coupling to G-proteins than do Dx receptors (Kimura
7
et al., 1995) . Quinpirole and pergolide represent D2 and D3 
selective agonists (Feldman, Meyer, & Quenzer, 1997) . 
Quinpirole, however, is more selective for D2 receptors than 
D3 receptors. Conversely, pramipexole, binds with a higher 
affinity to D3 receptors than D2 receptors (Bennett & 
Piercey, 1999) . Common D4 agonists consist of CP-226 and 
CP-269 (Oak, Oldenhof, & Van Tol, 2000) .
Antagonists also bind to receptor sites, however, they 
do not activate the receptor. Instead, antagonists prevent 
the endogenous neurotransmitter, and other molecules, from 
binding to and stimulating the receptor (Watkins,
Krogsgaard-Larsen, & Honore, 1990) . Typical Di/D5 receptor 
antagonists include SCH 23390, NNC-112, and SCH 39166 
(Gorelova & Yang, 2000 ). Selective D2 receptor antagonists 
include haloperidol, sulpiride, spiperone, and YM-09151-2. 
Nafadotride and PD 152255 are newly developed D3 receptor 
antagonists (Sobrian, Jones, Varghese, & Holson, 2003). 
Clozapine is representative of a D4 receptor antagonist (Van
Tol et al., 1991).
Both Di-like and D2-like dopamine receptors are 
guanosine triphosphate protein (G-protein) coupled 
receptors. As previously mentioned, D2-like receptors 
inhibit adenylyl cyclase activity. This inhibition is due 
to the fact that D2-like receptors are coupled to inhibitory
8
G-proteins (Gi) . Conversely, Di-like receptors are coupled 
to stimulating G-proteins (Gs< Goif) , and increase adenylyl 
cyclase activity (Baldessarini & Tarazi, 1996; Herve et al.,
2001). When activated, Gs proteins stimulate adenylyl 
cyclase, which converts adenosine triphosphate (ATP) into 
cyclic adenosine monophosphate, or cAMP (Baldessarini & 
Tarazi, 1996; Herve et al., 2001) . In turn, cAMP activates
protein kinase A (PKA), which effects both calcium and 
potassium permeability (Siegel et al., 1999).
The highest concentration of Di receptors are found in 
the caudate, putamen, nucleus accumbens, olfactory 
tubercles, and substantia nigra (Tarazi, Tomosine & 
Baldessorini, 1999). Low concentrations of Dx receptors
also reside in the neocortex, thalamus, cerebellum, and
septum (Wamsley, Alburges, McQuade, & Hunt, 1992) . D5 
receptors, in contrast, are essentially limited to the 
hippocampus and hypothalamus (Tarazi, Tomosine & 
Baldessorini, 1999). D2-like receptors have a pattern 
similar to Di-like receptors. For example, D2 and D3 
receptors are both found in high concentrations in the 
olfactory tubercles and the nucleus accumbens. In
addition, D3 receptors are found in the islands of Calleja.
D4 receptors are expressed in small quantities in the 
striatum (Van Tol et al., 1991), but are fairly prevalent in
9
the retina (Cohen, Todd, Harmon, & O'Malley, 1992),cerebral
cortex, amygdala, hypothalamus, and the pituitary (Asghari, 
Sanyal, Buchwaldt, Paterson, Jovanovic, & Van Tol, 1995; 
Valerio, Belloni, Gorno, Tinti, Memo, & Spano, 1994) .
Dopamine Pathways
Dopamine is found in two major pathways in the central 
nervous system: the nigrostriatal and the mesolimbic. In 
the mesolimbic system, dopamine is produced by neurons in 
the ventral tegmental area (VTA), which project to 
structures such as the prefrontal cortex and the basal 
forebrain, including the nucleus accumbens (McBride, Murphy, 
& Ikemoto, 1999; Wise & Bozarth, 1984). The mesolimbic
system is thought to be associated with reward (Bozarth,
1991). The mesolimbic system is stimulated by natural 
means; such as nutriment, predation, and intercourse, as
well as artificially by psychostimulants (Di Chiara, 1999;
Leshner & Koob, 1999; Wise & Bozarth, 1984).
Olds and Milner (1954) provided preliminary empirical 
evidence regarding reward and reinforcement in the 
mesolimbic system. These researchers electrically
stimulated the medial forebrain bundle (MFB), and found that
it was rewarding to subjects, as evidenced by repeat bar 
pressing. Additionally, lesioning the MFB disrupts reward 
mediated behavior (Wise & Bozarth, 1987). Due to the fact
10
that dopaminergic fibers terminate in the nucleus accumbens, 
Bozarth (1991) posits that the nucleus accumbens is the
central location of the rewarding action of drugs of abuse.
Researchers have since found that the activation of the
mesolimbic system results in increased locomotor activity
(Wise & Bozarth, 1987).
The second major dopamine pathway, termed the 
nigrostriatal pathway, extends from the substantia nigra to
the dorsal striatum; which contains the caudate and the 
putamen (White, 1996). Dopamine concentrations are at their 
highest in the caudate and putamen (Jaber, Robinson,
Missale, & Caron, 1996). The striatum is an important motor 
center, as dysfunctions in striatal dopamine have been found
to cause motor disorders such as Parkinson's disease and
Tourette's syndrome (Bennett & Piercey, 1999; Kurlan, Behr, 
Medved, & Como, 1988). The dorsal striatum is also 
implicated in habit learning such as learning to 
automatically perform complex motor tasks, such as driving
an automobile (Di Chiara, 1990). Moreover, the striatum is
now believed to be a component of a memory circuit
associated with craving (Volkow et al., 2002) and the
formation of habits associated with chronic drug use (White,
1996).
11
Morphine and Opioid Systems
Opioids are drugs that are widely used for their 
analgesic properties, but are also among the most abused 
drugs. The opioid compounds work by activating a group of 
g-protein coupled receptors. Three types of opioid 
receptors have been discovered: mu, delta, and kappa. All 
the opioid receptors are coupled to the inhibitory G- 
protein, Gi/O, which inhibits adenylyl cyclase activity and 
can directly open K+ and Ca++ channels (Waldhoer, Bartlett, & 
Whistler, 2004). Opioid receptors are distributed 
throughout the central nervous system, however, the nucleus 
accumbens, caudate putamen, and hypothalamus are 
particularly abundant in mu and delta receptors; while kappa 
receptors are primarily found in the hypothalamus, small 
quantities are also found in the caudate putamen and nucleus 
accumbens (Unterwald, Rubenfeld, Imai, Wang, Uhl, & Kreek, 
1995; Spangler, Ho, Zhou, Maggos, Yuferov, & Kreek, 1996).
There are four classes of endogenous opioid ligands, 
derived from precursor molecules via enzymatic processing, 
which activate mu, delta, or kappa receptors (Hertz, 1997). 
Beta endorphin is derived from the precursor pro­
opiomelanocortin and displays a high affinity for mu 
receptors and low infinity for delta receptors.
Proenkephalin gives rise to two types of enkephalins:
12
methionine and leucine. Enkephalins exhibit some
selectivity for delta receptors, while dynorphins show some 
selectivity for kappa receptors. Recent research has 
identified a fourth class of endogenous opioid ligand; 
endomorphin 1 and 2, which exhibits an extremely high 
selectivity for mu receptors (Zadina, Hackler, Ge, & Kastin,
1997).
The opioid system, like the dopamine system, is an 
important part of the neural reward circuitry. The 
reinforcing actions of opiates are largely mediated by the 
mu opioid receptor subtype. Much like psychostimulants, mu 
opioid agonists, such as morphine are readily self- 
administered by animals and induce conditioned place 
preferences. A large number of mu opioid receptors reside
in the VTA and nucleus accumbens and when activated increase
the release of dopamine(Di Chiara & North, 1992; Koob,
1992). This mu opioid-induced release of dopamine is 
believed to mediate the reinforcing properties of opiates. 
However, while some of the rewarding aspects of mu agonists 
are dopamine dependent other research has indicated that mu 
agonists also use dopamine independent pathways (Di Chiara &
North, 1992; Koob, 1992). Specially, these studies have
demonstrated that self-administration of morphine is not 
blocked by D2 antagonists. However, other studies suggest
13
that some dopamine antagonists (i.e. Di) can block, or 
partially block (i.e. 6-OHDA), morphine administration 
(Shippenberg & Herz, 1987; Shippenberg & Herz, 1988; Acquas, 
Carboni, Leone, & Di Chiara, 1989; De Fonseca, Rubio,
Martin-Calderon, Caine, Koob, & Navarro, 1995).
Methylphenidate and Other Psychostimulants
Overview
Psychostimulants are heterogeneous groups of compounds that 
share the ability to increase arousal and activity levels by 
activating the sympathetic nervous system, and increasing
levels of extracellular monoamines in the central nervous
system (Creese, 1982). These compounds have been medically 
utilized for their stimulant properties for many years 
(Creese, 1982) . For example, psychostimulants are used to
increase attention levels in ADHD and to increase arousal
levels in narcolepsy (Solomon, White, Parron, & Mendelson, 
1979). In addition to these neuropsychiatric disorders, 
psychostimulants are used to treat obesity as they increase 
body metabolism and suppress appetite (Martin, Sloan,
Sapira, & Jasinski, 1971; Silverstone, 1981).
Unfortunately, the stimulant properties of these drugs are 
also exploited recreationally as psychostimulants are among
14
the most addictive and abused class of drugs (Fischman &
Haney, 1999).
Mechanisms- of Action
Cocaine and amphetamine are prototypical 
psychostimulants that increase synaptic levels of monoamine 
neurotransmitters (Creese, 1982). Cocaine increases 
synaptic levels of monamines by inhibiting the actions of 
dopamine, norepinephrine, and serotonin transporter sites; 
however, the reuptake inhibiting actions of cocaine are much 
more prominent at dopamine and serotonin synapses (Deutsch & 
Schweri, 1994; Kuczenski & Segal, 1997; Pan et al., 1994;
Schenk & Izenwasser, 2002) . Amphetamine also increases 
dopamine levels, as well as extracellular levels of 
norepinephrine and serotonin (Kuczenski & Segal, 1997) . 
Compared to cocaine, amphetamine has a more complicated 
mechanism of action as it increases monoamine levels by 
reversing the direction of the monoamine reuptake pumps, 
blocking reuptake, and by acting as a monoamine oxidase 
inhibitor (Yokel & Wise, 1975). Amphetamine's ability to 
reverse monoamine transporters to release newly synthesized 
dopamine and norepinephrine appears to be the most important 
of its pharmacological actions (Fumagalli, Gainetdinov,
Wang, Valenzano, Miller, & Caron, 1999). This releasing 
action leaves vast quantities of dopamine and norepinephrine
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free in the synaptic cleft, and produces the 'rush' reported 
by drug users (NIDA, 1999).
The psychostimulant, methylphenidate, is structurally 
related to amphetamine but has a mechanism of action similar 
to cocaine. That is to say, methylphenidate increases
monoamine levels in the synapse primarily by blocking 
transporter sites. However, methylphenidate, unlike 
cocaine, has a very low affinity for the serotonin 
transporter, and, consequently, is a poor in vitro inhibitor 
of serotonin uptake (Pan et al., 1994; Schenk & Izenwasser, 
2002). Methylphenidate also appears to increase the release 
of monoamines using a mechanism similar to amphetamine; 
through interaction with monoamine transporters.
Behavioral Effects of Psychostimulants
Acute Effects in Animals
Psychostimulant administration produces a wide range of 
behavioral actions. In rodents, acute psychostimulant 
exposure primarily induces locomotor activity at low to 
moderate doses while producing intense oral sterotypies at 
higher doses (Kelly & Iversen, 1976; Taylor & Snyder, 1971; 
Tirelli, Laviola, & Adriani, 2003; Yang, Amini, Swann, & 
Dafny, 2003) . For example, acute injections of low doses of 
methylphenidate (under 2.0 mg/kg) produce no significant
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effects on locomotor activity (Yang et al., 2003), while 
acute injections of methylphenidate at high doses (2.5 to 40 
mg/kg) produce immediate locomotor effects (Yang et al., 
2003). Similarly, low doses of cocaine, and particularly 
amphetamine, cause an increase in locomotor activity, while 
higher doses of both psychostimulants induce pronounced 
stereotyped behavior (Kelly & Iversen, 1976) .
Acute Effects in Humans
Low doses of acute amphetamine in humans results in
feelings of well-being, increased competence and alertness, 
as well as reduced appetite (NIDA, 1998). Higher doses of 
acute amphetamine can cause tremors, sweating, and heart 
palpitations in humans (NIDA, 1998). Low doses of acute 
cocaine in humans results in a variety of subjective effects 
including: euphoria, talkativeness, increased energy and
mental alertness (NIDA, 1999). Low doses of acute cocaine
in humans also produces physiological effects such as: 
dialated pupils, increased temperature, heartrate, and blood 
pressure (NIDA, 1999j . High doses of acute cocaine results 
in bizarre, erratic, and violent behavior (NIDA, 1999).
Acute administration of low doses of methylphenidate in
humans results in elevated blood pressure, tachycardia,
increased respiration, suppressed appetite, and sleep 
depravation (NIDA, 2001). Acute administration of high
17
doses of methylphenidate can cause delirium, aggressiveness, 
panic states, and hallucinations (Morton & Stockton, 2000) . 
Chronic and Repeated Effects
In rodents, repeated intermittent exposure to cocaine 
and amphetamine result in a phenomenon called reverse
tolerance or behavioral sensitization (Kalivas & Stewart,
1991). This phenomenon is characterized by a progressive 
and enduring enhancement of the drug-induced behavioral 
effects of psychostimulant compounds (Kalivas & Stewart, 
1991; Robinson & Berridge, 2001; Sorg & Newlin, 2002).
Behavioral sensitization can be observed after as little as
one drug exposure and can still be detected for at least a 
year after the last drug exposure (Kalivas & Stewart, 1991; 
Robinson & Becker, 1986) Much of the interest generated by 
behavioral sensitization stems from its utility as an animal 
analog of human psychosis (Kalivas & Stewart, 1991) and as a 
model of human drug addiction (Davidson, Gow, Lee, & 
Ellinwood, 2001) . Repeated injections of methylphenidate 
can also produce behavioral sensitization, with exponential 
dosage increases resulting in tolerance (Yang et al.,
2003) .
Marked neurotoxic effects can occur during chronic and 
repeated psychostimulant dosing schedules (Davidson, Gow, 
Lee, & Ellinwood, 2001). For example, exposure to high
18
doses of methamphetamine causes long lasting reductions in 
dopamine content, tyrosine hydroxylase activity, decreased 
dopamine release, and reductions in the number of dopamine 
transporters (Bowyer et al., 1992; Eisch, Gaffney,
Weihmuller, O'Dell, & Marshall, 1992; Kokoshka,
Fleckenstein, Wilkins, & Hanson, 2000; O'Dell, Weihmuller, &
Marshall, 1993; Ricaurte, Schuster, & Seiden, 1980; Sabol,
Roach, Broom, Ferreira, & Preau, 2001; Wagner, Ricaurte,
Johanson, Schuster, & Seiden, 1980).
In humans, repeated amphetamine administration produces
paranoia, delusions, hallucinations, and violent behavior 
(NIDA, 1998). Chronic administration of cocaine in humans
also produces several changes in behavior including:
irritability, mood disturbances, restlessness, paranoia, and 
auditory hallucinations (NIDA, 1999). Chronic 
administration of methylphenidate can result in psychotic 
symptoms similar to amphetamine (Morton & Stockton, 2000) .
Abuse Potential
Both amphetamine and cocaine are highly addictive and
widely abused drugs (Kollins, MacDonald, & Rush, 2001) . The
National Household Survey on Drug Abuse (2000) estimates
1
that 4.0% of the population have tried methamphetamine at 
some point in their lives. The National Institute on Drug 
Abuse (1999) reports that 1.5 million Americans age 12 and
19
older are chronic cocaine users, and 0.9 million abuse
methylphenidate. Increases in the recreational usage of 
methylphenidate has raised concerns regarding its abuse 
potential (Johnston, O'Malley, & Bachman, 2003; DEA 
Congressional Testimony, 2000). The illicit use and abuse 
of methylphenidate is well known, and has been documented 
throughout recent decades. The illicit use of
methylphenidate among high school seniors increased from 
0.1% in 1992 to 2.8% in 1997 (Johnston, O'Malley, & Bachman, 
2003). Methylphenidate is abused orally (Lucas and Weiss, 
1971), intranasally (Jaffe, 1991), and through intravenous 
administration (Levine, Caplan, & Kauffman, 1986) . Volkow 
and colleagues (1995) found that when methylphenidate is 
abused intranasally, the effects are similar to the
intranasal use of amphetamine.
Psychostimulant Neurotoxicity 
One proposed mechanism for psychostimulant-induced 
toxicity is the production of free radicals. A free radical 
is a molecular species with an unpaired electron. High-dose
administration of amphetamine and its analogues increase
free radicals (Colado et al., 1997; Fleckenstein et al.,
1997; Giovanni, Liang, Hastings, & Zigmond, 1995).
Molecular oxygen is then released via enzyme degradation and
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through ngn-enzymatic means (auto-oxidation) (Davidson, Gow, 
Lee, & Ellinwood, 2001). The enzyme MAO metabolizes 
dopamine to DOPAC and hydrogen peroxide. The resulting 
oxygen molecules become highly reactive with other 
molecules, hence, they, are termed reactive oxygen species 
(ROS). ROS eventually'reacts with hydrogen peroxide forming 
a hydroxyl free radical (Feldman et al., 1997) . These free 
radicals are actually produced during the normal functioning 
of cells, however, they are kept in balance by antioxidants.
In the case of a hydroxyl free radical, there is no existing 
enzyme reactive enough to remove it (Feldman et al., 1997). 
This is dangerous because necrotic cell death can occur
(Davidson et al., 2001).
Necrotic cell death is induced by a chain reaction that
occurs from the reaction between free radicals and a non­
radical compound. Necrosis does not affect individual 
cells, but is marked by swelling and inflammation of the 
cell in general, as well as the mitochondria (Brown & 
Yamamoto, 2 0 03) . Methamphetamine specifically has the 
ability to disrupt the electrical gradient of mitochondrial 
plasma membranes.- This eventually results in the cells 
contents being ousted, and the cell dying (Davidson et al.,
2001). In the case of methamphetamine administration, 
necrosis may be favored over apoptosis due to ROS formation
21
and mitochondrial inhibition (Brown & Yamamoto, 2 0 03) .
Apoptotic cell death is an irreversible mechanical 
injury to the cell. Apoptosis affects individual cells and 
is characterized by cell shrinkage and fragmentation. The 
pattern of events in apoptosis is so orderly that the 
process if often called programmed cell death. The process 
of apoptosis is intimately intertwined with mitochondria. 
Mitochondria produces adenosine triphosphate (ATP), which is 
the energy the cell.utilizes to carry out its various 
functions. The activation of apoptosis requires ATP. 
Hyperthermia increases the utilization of cellular ATP, 
providing a potential basis for amphetamines induction of 
necrosis over apoptosis (Madl & Allen, 1995). The absence 
or presence of ATP depletion, in conjunction with the 
inhibition of mitochondrial function, may play a role in 
determining which type of cell death is induced (Leist, 
Single, Castoldi, Kuhnle, & Nicotera, 1997;- Qian, Herman, &
Lemasters 1999). The mechanisms involved in the switch from
apoptosis to necrosis are not fully understood, but changes
within the mitochondria are indicated (Brown & Yamamoto,
2003). Dopaminergic neurons have a very high energy demand,
making them particularly sensitive to mitochondrial damage
(Davidson et al., 2001) . Both apoptotic and necrotic cell 
death appear to contribute to psychostimulant neurotoxicity.
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Due to the massive influx of dopamine into the 
extracellular space upon psychostimulant introduction, the 
second consideration of neurotoxic effects must necessarily
involve neurotransmitter levels. Excessive monoamine
levels, due to psychostimulant exposure, inevitably lead to 
the activation of apoptotic and necrotic mechanisms.
Besides an obvious reduction in dopamine stores, a 
downregulation of D2-like receptors is also likely to occur. 
This takes place because the remaining receptors must now 
compensate for the receptors that are no longer functioning. 
As dopaminergic receptors are killed off by the neurotoxic 
effects of the drugs, the system becomes downregulated, and 
the surviving receptors often become sensitized due to their
now reduced numbers (Nader et al., in press). The inverse 
of this effect is the increase of receptors, known as 
upregulation. The increase in the numbers of receptors is 
often accompanied by desensitization. It has been widely 
noted that the neurotoxicity caused by the various 
amphetamine analogs results in long-term reductions in 
dopamine content (Clausing et al., 1995; Fields, Wichlinski, 
Drucker, Engh, & Gordon, 1995). On the other hand, other 
psychostimulants, such as cocaine, have failed to yield 
long-term dopaminergic deficits (Capon et al., 1997; Eleven, 
Perry, Woolverton, & Seiden, 1990; Yeh & De Souza, 1991;) .
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Ontogeny of Dopamine Systems
Ontogeny of Dopamine Receptors
Determining the precise ontogeny of D± and D2 receptors
has proved difficult as conflicting results of the
development of dopamine receptors have been reported.
However, it is clear that dopamine receptors are present 
very early in development as both striatal D2 mRNA and D2 
receptor binding have been detected prenatally in rats (De
Vries, Mulder, Schoffelmeer, 1992; Schambra, Duncan, Breese,
Fornaretto, Caron, & Fremeau, 1994) . Di mRNA has also been
detected as early as gestational day 11, but the receptors 
are not detectable prenatally (Broaddus & Bennet, 1990;
Cadoret, Jaber & Bloch, 1993). Development of both Di and D2 
dopamine receptors appears to be complete by the third or 
forth postnatal week (Broaddus & Bennett, 1989; De Vries et 
al., 1992; Schambra et al., 1994). Dx receptors, however, 
appear to reach adult levels faster than D2 receptors
(Broaddus & Bennett, 1989; Rao, Molinoff, & Joyce, 1991;
Schambra et al., 1994). During the periadolescent period
(PND 34-46) striatal Di and D2 receptors actually increase
above adult levels and are pruned down once adulthood is
reached (Andersen, 2003; Teicher, Krenzel, Thompson, &
Andersen, 2 0 03) .
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Ontogeny of Psychostimulant-Induced Behavior
Psychostimulants have a multitude of effects in the
developing CNS. These effects are usually similar to those 
found in adults, however, ontogenetic differences do exist. 
For instance, acute injections of psychostimulants increase 
activity in both adults and pups, while chronic or repeated 
dosing schedules produce differential effects (Kalivas & 
Stewart, 1991; Robinson & Berridge, 2001). Specifically, 
repeated exposure to psychostimulants causes a progressive 
and long-lasting increase in psychomotor activating effects, 
a phenomenon which is referred to as behavioral
sensitization (Robinson & Becker, 1986). In adult rats,
repeated exposure to psychostimulants in general results in 
sensitization that can be detected long (i.e., up to a year) 
after the cessation of drug administration (Robinson & 
Becker, 1986). In contrast, behavioral sensitization does
not occur until the first week postnatally, moreover, 
expression of the sensitized response is transient upon the 
cessation of drug administration. For example, when either 
methylphenidate or amphetamine was administered for 4 or 5 
days to rats at PD 10-11 or 16-17, sensitization was 
exhibited when tested 1 or 2 days after the cessation of the 
dosing regimen, but not 1 week later (McDougall, Collins, 
Karper, Watson, & Crawford, 1999; McDougall, Duke, Bolanos,
25
& Crawford, 1994) . The long-term retention of behavioral
sensitization matures progressively and is not complete
until the third postnatal week (Tirelli, Laviola, & Adriani,
2003).
Ontogeny of Psychostimulant Toxicity
High doses of methamphetamine alter dopaminergic
neurons in the adult rat (Davidson et al., 2001) . Numerous
research studies have shown that high doses of
methamphetamine cause long-term changes in dopamine content, 
tyrosine hydroxylase activity, decreased dopamine release, 
and reduced numbers of dopamine transporters (Bowyer et al.,
1992; Eisch et al., 1992; Kokoshka et al., 2000; Ricaurte et
al. , 1980; O'Dell et al., 1993; Sabol et al., 2001; Wagner 
et al., 1980) . However, early postnatal exposure to 
amphetamine and its analogs have less of an effect on 
dopamine levels in comparison with exposure in adults 
(Lucot, Wagner, Schuster, & Seiden, 1982; Miller, 
O'Callaghan, & Ali, 2000; Wagner et al., 1980). While the 
cause of this differential response to amphetamine 
administration is unknown, it is possible that it is due to 
an underdeveloped dopaminergic system in rat pups. For 
example, a study comparing the dopaminergic reuptake system 
in 5-day old rat pups and adult rats found that the rat pups 
were less efficient at removing dopamine from the
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extracellular environment as compared to adult rats (Gazzara
& Andersen, 1997) . This difference in the amount of dopamine 
removed is explained by fewer uptake sites in the pups due 
to immature nerve terminals (Coulter, Happe, & Murrin, 1996; 
Voorn, Kalsbeek, Jorritsma-Byham, & Groenewegen, 198 8) .
In contrast to the inability of amphetamine and
derivatives to cause changes in dopaminergic markers in 
young animals, several studies have indicated that early 
psychostimulants do have long-term effects when assessed in
adulthood. For instance it has been found that neonatal
exposure to methamphetamine causes learning impairments on 
cognitive tests in adult rats (Vorhees, Ahrens, Acuff-Smith, 
Schilling, & Fisher, 1994; Vorhees, Inman-Wood, Morford, 
Broening, Fukumura, & Moran, 2000) . More specifically, 
deficits in spatial learning and memory were found after 
neonatal methamphetamine treatment (Vorhees et al., 1994; 
2000). This research indicates that the neonatal period, up 
to at least PD 20, is extremely sensitive to the effects of 
a wide range of psychostimulants. In addition to the long­
term effects on learning and memory, a recent study has 
found that preweanling rats exposed to methamphetamine
exhibited a reduction in dorsal striatal D2-like binding 
sites and dopamine levels that were still detectable into
adulthood (Crawford et al., 2003).
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Thesis Statement
The most commonly diagnosed childhood behavioral 
disorder is ADHD, which is widely treated with the 
psychostimulant methylphenidate (Swanson, Seargeant, Taylor, 
Sonuga-Barke, Jensen, & Cantwell, 1998). Recent studies 
have indicated that early methylphenidate exposure may have 
long lasting effects, espeically on drug responsivity in 
adult rats and humans. Thus, the purpose of this research 
project is to determine whether chronic treatment with 
methylphenidate during the preweanling period will alter the 
reinforcing properties of morphine in young adult rats. To 
determine whether morphine is reinforcing, the condition 
place preference (CPP) paradigm was used. CPP has been used 
extensively to measure drug reward (Bardo, Rowlett, &
Harris, 1995) . The basic premise of CPP holds that when a 
drug (US) is paired with contextual cues (CS), the 
environmental stimuli acquires the properties of the US. In
the CPP paradigm, a drug is repeatedly administered in the 
same distinctive environment, resulting in the animal 
associating the drug effect with the environment. Each
chamber within the CPP apparatus differs in the visual,
somatosensory, and olfactory cues, which provides distinct 
environments (Stolerman, 1992) . Following the appropriate 
number of conditioning trials, the experimental animals are
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allowed to choose freely between the drug-paired and the 
drug-free chamber. Time spent in the drug-paired chamber, 
relative to the drug-free chamber, is indicative of place 
preference, and is considered a behavioral measure of a 
drug's reinforcing effect. In the majority of CPP 
experiments, the vehicle (typically saline) and the drug are 
paired with different compartmental environments (Bardo et 
al. , 1995) . An increase in the amount of time spent in a 
chamber that had previously been paired with a drug is 
believed to be analogous to drug seeking behavior in human 
subjects. CPP is now believed to model the motivation 
elicited by environmental stimuli involved in drug-taking
behavior (Bardo et al. , 1995) .
After preference for the morphine- and saline-paired 
compartments are determined, the rats were sacrificed and 
the number of dopamine D2 receptors measured. I predict 
that rats given early methylphenidate exposure will (a) 
spend a greater amount of time in the morphine-paired 
environment than saline-exposed rats and (b) preference for 
the drug-paired compartment will be negatively correlated 
with the number of dopamine D2 receptors.
If the results showed that early methylphenidate 
exposure increases drug preference and decreases dopamine 
receptors; it supports the hypothesis that there is a
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biological reason for increased drug use after
methylphenidate treatment. If the results showed that early
methylphenidate treatment does not change drug preference or 
dopamine receptors, this supports the hypothesis that early 
methylphenidate treatment does not increase the probability
of later drug use.
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CHAPTER THREE
METHODS AND MATERIALS
Subj ects
Subjects were 108 male and female rats of Sprague- 
Dawley descent (Harlan), born and raised at California State 
University, San Bernardino. Litters were culled to ten pups 
by 3 days of age, and kept with the dam throughout
behavioral testing. Pups were kept with the dam until PND 
25, at which time they were weaned and placed in group cages 
with same-sex litter mates. Only one rat from each litter 
was placed into a particular group. The colony room was 
maintained at 22-24°C and kept under a 12-hr light/dark 
cycle. Behavioral testing was done during the light cycle, 
at approximately the same time each day. Subjects were 
treated according to the American Psychological Associations 
"Ethical Principles" (1992), and the Principles of
Laboratory Animal Care (National Institute of Health
Publication # 85-23) .
Apparatus
CPP was done in T-shaped wooden chambers comprised of
three compartments. The two large end compartments (24 x 30
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x 45 cm) are adjacent to each other and are separated by a
removable partition. The small compartment (the placement
chamber, 24 x 10 x 45 cm) projects out from the junction
between the large compartments. A second removable
partition enables rats to enter either of the large
compartments from the placement chamber. The odor,
flooring, and color of each compartment vary. One of the 
large end compartments has white walls, wire mesh flooring, 
and pine bedding, whereas the other large end compartment 
has black walls, metal rod flooring, and cedar bedding. The 
placement chamber has a solid wood floor and is painted
gray.
In Vivo Drug Treatment
Starting at PND 10, rats received daily injections of 
methylphenidate (0.0, 2.0, or 5.0 mg/kg, ip). These daily 
injections continued for 10 consecutive days.
Morphine-Induced Conditioned Place Preference 
Procedure
Following acclimation to handling, a total of 108 
sixty-day-old rats from the three pretreatment conditions 
were randomly assigned to groups. A 10-day biased CPP 
procedure was used, which included one preconditioning day,
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eight conditioning days (consisting of alternating daily 
injections of saline or morphine) and one test-day. On the 
preconditioning day, rats received no injection and were put 
in the gray placement chamber of the apparatus. After rats 
entered either the black or white conditioning compartment,' 
access to the placement chamber was blocked and rats were
allowed 15 minutes access to the black and white
compartments. On the conditioning days, rats either
received an injection of morphine (0, 2, or 5 mg/kg, sc) and 
were placed in their non-preferred compartment or they 
received an injection of saline and were placed in their 
preferred compartment. Initial drug order was 
counterbalanced between groups. Conditioning sessions lasted 
30 minutes. On the test day, rats were left uninjected and 
given free access to the black and white compartments for 15
minutes.
All conditioning and test days were videotaped and time 
spent in the non-preferred compartment and locomotor 
activity was scored by experimenters blind to treatment 
conditions. Locomotor activity was assessed by dividing the 
two end compartments into four equal quadrants and counting
the number of times each rat crosses into a different
quadrant. In summary, a 2 x 3 x 3 (sex x pretreatment
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condition x drug group) experimental design was used. There
was a total of six rats per group.
Membrane Preparation
Immediately following behavioral testing, rats were
sacrificed and their dorsal striata removed. The tissue was
stored at -80° C until time of assay. On the assay day, 
tissue was thawed on ice and crude membrane homogenates was 
made using the following protocol. Striatal sections from 
each rat were homogenized in 100 volumes of 50 mM Tris-HCl 
buffer (pH 7.4) for approximately 20 s using a Brinkmann
Polytron. The homogenates were centrifuged at 20,000 x g
for 20 minutes. The pellet was resuspended in 100 volumes
of the same buffer and centrifuged again at 20,000 x g for
20 minutes. The final pellet was suspended in approximately 
30 volumes of buffer (pH 7.4). Protein concentrations for
the final pellet were determined using the Bio-Rad Protein 
Assay with BSA as the standard.
Homogenate Ligand Binding Assay 
For the D2 receptor binding assay, tissue suspensions
(50-100 jiig/protein) were added to duplicate tubes containing 
50 mM Tris, 2 mM NaCl2, 5 'mM KCl, 1 mM MgSO4< and 2 mM CaCl2
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(pH 7.4) at a final volume of 1 ml. The tubes also included 
[3H]-spiperone in concentrations ranging from 0.05 to 0.6 
nM. Non-specific binding was determined in the presence of 
10 /iM (--)-sulpiride. The incubation time for the assay was 
3 0 minutes at 37° C. Incubation was terminated by vacuum 
filtration over glass fiber filters (Whatman GF/B, 
pretreated with 0.1% polyethylenimine). Filters were washed 
twice with ice-cold Tris-HCl buffer and radioactivity was 
measured by liquid scintillation spectrometry. Dopamine D2 
binding sites (Bmax) and affinity (Kj) was determined using 
nonlinear regression using Prism (GraphPad Software).
Statistics
Preference scores (time spent in the non-preferred 
compartment on the test day minus the time spent in the same 
compartment on the preconditioning day), locomotor activity, 
D2 binding data (i.e., Bmax and Kj) was analyzed by separate
2x3x3 (sex x pre-exposure drug x conditioning drug)
analyses of variance (ANOVA's). Tukey tests were used for 
post hoc comparisons. A Pearson correlation coefficient was 
also used to assess the relationship between the preference
for the drug paired room and the number of dopamine D2
binding sites.
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CHAPTER FOUR
RESULTS
Body Weight
During the 10 days of drug administration (i.e., PD 11- 
20), body weight was not significantly affected by 
methylphenidate treatment and both males and females 
exhibited steady weight gain throughout the injection 
procedure [day main effect; F(9, 95) = 2017.17, p < 0.001, 
Tukey tests, p < 0.05; see Figure 1]. Body weight, however, 
did differ between sexes during the early drug treatment as 
males were significantly heavier than females on each
injection day [sex x day interaction; F(9, 95) = 5.51, p <
0.001; Tukey tests, p < 0.05].
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Figure 1. Mean Body Weights 
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Conditioned Place Preference
Regardless of sex or pretreatment group, rats exhibited 
morphine-induced CPP, as rats treated with 5.0 mg/kg 
morphine had significantly greater difference scores than 
saline-treated rats [drug main effect; F(2, 101) = 7.76, p < 
0.01; Tukey tests, p < 0.05; see Figure 2]. Rats treated 
with the lower dose of morphine (0.5 mg/kg) did not show a 
preference for the drug-paired room and sex did not 
significantly affect place conditioning. Interestingly, the 
preference induced by morphine was altered by 
methylphenidate pretreatment. Specifically, rats pretreated 
with 5.0 mg/kg methylphenidate had greater preference scores 
than rats treated with saline or 2.0 mg/kg methylphenidate 
[post-treatment main effect; F(2, 32) = 4.45, p < 0.02;
Tukey tests, p < 0.05; see Figure 2].
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Figure 2. Mean Preference Score on Test Day. Rats Were Given 
Alternating Daily Injections of Morphine (0.0, 0.5, or 5.0 
mg/kg) and Saline from Postnatal Day 61. to Postnatal Day 68. 
a Indicates a significant difference from rats treated with 
0.0 or 0.5 mg/kg morphine (post-treatment main effect) . 
b Indicates a significant difference from rats pre-exposed 
to 0.0 or 2.0 mg/kg methylphenidate and treated with 5.0 
mg/kg morphine.
39
Locomotor Activity
Locomotor activity (i.e., line crosses) was assessed on
the first and last day of drug administration in the drug or 
non-preferred chamber. Over these two testing periods, 
female rats expressed greater levels of locomotor activity 
as compared to male rats regardless of methylphenidate 
pretreatment or morphine exposure [sex main effect; F(l, 89) 
= 5.93, p < 0.05; see Figure 4]. Overall there were no 
differences in locomotor activity induced by the saline or 
the two doses in morphine for male or female rats. However, 
rats 'treated with 5 mg/kg morphine had similar levels of 
locomotor activity on both testing days whereas rats treated 
with saline or 0.5 mg/kg morphine had significant reductions 
in locomotor activity on the second day of testing [drug by 
day interaction; F(2, 89) = 8.68, p < 0.01; Tukey tests, p < 
.05; see Figure 3]. Methylphenidate pretreatment also 
affected locomotor activity, but only in female rats. 
Specifically, female rats pretreated with 2.0 mg/kg 
methylphenidate showed significantly less locomotor activity 
than similarly treated females pretreated with saline [sex 
by pretreatment interaction; F(2, 89) = 4.61, p < 0.02;
Tukey tests, p <.05; see Figure 4] .
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Figure 3. Mean Locomotor Activity on the First and Last Day 
of Drug Administration During Conditioned Place Preference 
Conditioning. During Conditioning, Rats Were Injected with 
Either 0.0, 0.5, or 5.0 mg/kg Morphine.
a Indicates a significant difference from similarly treated 
rats on day 1.
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Figure 4. Mean Locomotor Activity for Male and Female Rats 
During Conditioned Place Preference Conditioning. 
a Indicates a significant difference between male and female
rats (sex main effect).
b Indicates a significant difference from female rats 
pretreated with 0.0 mg/kg methylphenidate.
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D2 Receptor Binding
Neither D2 binding densities (i.e., Bmax) or affinity
(i.e., Kd) were altered by methylphenidate pretreatment or
morphine exposure. However, there was a significant
positive correlation between the number of D2 binding sites 
and morphine-induced preference scores (r = 0.32, p < 0.05, 
see Figure 5). When this relationship was examined within 
each pretreatment group, a positive correlation was only 
found for rats in the saline and 5.0 mg/kg methylphenidate 
pretreatment groups (r = .62, p < .05; r = .82, p <. 01, 
respectively; see Figures 6 and 7), but not for rats 
pretreated with 2.0 mg/kg methylphenidate. Because rats 
conditioned with saline and 0.5 mg/kg of morphine failed to 
exhibit a conditioned place preference, only rats in the 5.0 
mg/kg condition were used in the analysis.
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All MPH Groups
Figure 5. Correlation Between Preference Scores and Number 
of Dopamine D2-Like Binding Sites in Rats Pretreated with 
Methylphenidate (0.0, 2.0, or 5.0 mg/kg) from Postnatal Day 
11 to Postnatal Day 20 and Conditioned with 5 mg/kg 
Morphine.
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Saline
Figure 6. Correlation Between Preference Scores and Number 
of Dopamine D2-Like Binding Sites in Rats Pretreated with
Saline from Postnatal Day 11 to Postnatal Day 20 and 
Conditioned with 5 mg/kg Morphine.
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5 mg/kg MPH
Figure 7. Correlation Between Preference Scores and Number
of Dopamine D2-Like Binding Sites in Rats Pretreated with 
5.0 mg/kg Methylphenidate from Postnatal Day 11 to Postnatal 
Day 20 and Conditioned with 5 mg/kg Morphine.
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CHAPTER FIVE
DISCUSSION
Overview
The purpose of the present study was to determine 
whether chronic treatment with methylphenidate during the 
preweanling period would alter the reinforcing properties of 
morphine in young adult rats. To this end, we determined
whether early exposure to methylphenidate would alter
morphine-induced CPP in young adult rats. In addition, we 
also examined whether dopamine D2 binding sites would be
affected by early methylphenidate treatment and if the 
number of sites would be correlated with morphine-induced 
CPP. Two hypotheses were made regarding the effects of 
early methylphenidate treatment on morphine-induced CPP and 
D2 binding sites. Specifically, it was predicted that rats 
pre-exposed to methylphenidate would: (1) have greater 
preference scores as compared to saline pre-exposed rats, 
and (2) have fewer D2 receptors than saline exposed rats.
In addition, we hypothesized that there would be a negative 
correlation between preference scores and the number of D2
binding sites.
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Effects of Methylphenidate Pre-Exposure 
on Morphine-Induced Conditioned Place
Preference
Consistent with numerous other reports, young adult
rats in the present study exhibited a morphine-induced CPP, 
as rats spent significantly more time in the intially non- 
prefered compartment after morphine conditioning as compared 
to saline treated rats (for reviews see Bardo et al., 1995; 
McBride et al., 1999) . However, this increased preference 
for the drug-paired compartment was only observed in rats 
conditioned with the high dose of morphine (i.e., 5 mg/kg), 
but not the low dose (i.e., 0.5 mg/kg). This dose effect 
was not unexpected as a previous meta-analysis of morphine- 
induced CPP showed that doses between 1 and 10 mg/kg were 
fairly equivalent in producing place preference, while doses 
under 1 mg/kg where found to be suboptimal (Bardo et al.,
1995) .
Early exposure to 5 mg/kg methylphenidate, as 
orginially predicted, increased the magnitude of the
morphine-induced CPP. This result suggests that exposure to 
methylphenidate during the preweanling period increases the 
rewarding value of morphine. This conclusion is consistent
with studies showing that exposing adolescent rats and mice
to methylphenidate enhances both cocaine self-administration
and cocaine-induced CPP (Achat-Mendes et al., 2003; Brandon
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et al., 2001). However, these results contrast with studies
using preadolescent rats, in which early methylphenidate
exposure decreased cocaine-induced CPP (Andersen et al., 
2002; Carlezon et al., 2003). Taken together, it appears 
that age at drug exposure may be critical for determining 
the long-term impact of methylphenidate. Specifically, 
methylphenidate exposure during the preadolescent period may 
decrease later drug responsiveness, while exposing rats to 
methylphenidate during earlier (preweanling) or later 
(adolescent) developmental periods may enhance drug
responsiveness.
Interestingly, enhanced morphine-induced CPP was only 
observed in rats pre-exposed to the 5 mg/kg dose of 
methylphenidate. This dose effect was not anticipated, as a 
previous study using adolescent rats had found that 2 mg/kg 
methylphenidate was sufficient to enhance the rewarding 
effects of cocaine in a self-administration paradigm. This 
may be suggestive of an age-dependent difference in the 
sensitivity to repeated methylphenidate treatment (i.e.,
adolescent rats are more sensitive than preweanling rats). 
Alternatively, the self-administration paradigm may be a
more sensitive tool for assessing changes in reward value.
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Early Methylphenidate Pre-Exposure and 
D2 Receptors
The present study, as well as the previously mentioned 
developmental methylphenidate studies, demonstrated that 
early methylphenidate exposure can alter drug-rewarded 
behavior. The neurobiological cause of this alteration in
rewarded behavior is unknown, but changes involving D2 
receptors may be responsible. Evidence for D2 receptor 
involvement is threefold: first, several studies using D2 
antagonists and D2 knock-out mice have demonstrated the 
importance of D2 receptors for drug-rewarded behaviors (Di 
Chiara, 1999; Risinger, Freeman, Rubinsten, Low, & Grandy,
2000; Salamone, Cousins, & Snyder, 1997; Noble, 1996; Smith, 
Fetsko, Xu, & Wang, 2002); second, early exposure to
methamphetamine (a psychostimulant similar to
methylphenidate) has been reported to cause a decline in D2 
receptors that is detectable in adulthood (Crawford et al., 
2003); and third, human imaging studies have demonstrated
that addiction to psychostimulants and other abused drugs is
associated with lower levels of D2 receptors and that the
number of striatal D2 receptors in nondrug-abusing subjects 
is negatively correlated with the reinforcing value of 
methylphenidate (Volkow et al., 2002; 2004). Thus, based on
evidence from both the animal and human literature, we
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predicted that D2 receptor binding sites would decline after 
early methylphenidate treatment, thus providing a mechanism 
for changes in morphine-induced reward. Moreover, we 
hypothesized that the number of D2 receptors would be 
negatively correlated with morphine-induced preference
scores.
Our hypothesis regarding changes in D2 receptor sites 
was not supported, because we found that the number of D2 
receptors was not effected by early methylphenidate 
exposure. Interestingly, however, the number of D2 
receptors was positively correlated with morphine-induced 
preference scores. It is not known why morphine-induced CPP 
was positively correlated with D2 receptors, while the 
rewarding effects of other drugs (i.e., methylphenidate and 
alcohol) were found to have negative relationship to D2 
receptors is unknown (Volkow et al., 2002; 2004). It is 
possible that exposure to morphine changed the number of D2 
binding sites. Alternatively, the positive association
between D2 binding sites and morphine-induced CPP may be 
applicable to only morphine and not other drugs of abuse. 
This alternative is supported by a study showing that D2
knock-out mice do not acquire morphine-induced CPP, but they
do show normal cocaine-induced CPP (Smith et al., 2002),
51
suggesting that morphine-induced CPP is dependent on D2 
receptors while cocaine-induced CPP is not.
Implications and Conclusions
In accordance with previous research, the present study 
provides additional evidence that early exposure to 
methylphenidate causes behavioral adaptations that persist 
into adulthood. Our results show that exposure to 
methylphenidate during the preweanling period increases the 
rewarding value of morphine. These results suggest that 
treating young children (e.g. preschool age) with 
methylphenidate may be putting them at risk for drug
addiction later in life.
The finding that higher levels of D2 receptors were 
associated with morphine-induced CPP may reflect 
inadequacies in the current dopamine deficiency theory of 
addiction. The current understanding is that decreased CPP
should be associated with higher levels of D2 receptors and
increased CPP is associated with lower levels of D2
receptors. This association does not hold true for our 
findings. It may be possible that the theory does not apply 
to morphine-induced reward, because greater preference 
scores should also be exhibited by rats treated with saline 
that have higher levels of D2 receptors.
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In summary, rats pretreated with methylphenidate showed
greater preference scores than saline pretreated rats. In 
particular, early exposure to 5 mg/kg methylphenidate 
increased the magnitude of morphine-induced CPP, which 
supports our original hypothesis and suggests that exposure 
to methylphenidate in the preweanling period increases the 
rewarding value of morphine. This finding indicates an age- 
dependent mechanism for assessing long-term drug exposure. 
This evidence presupposes that preweanling rats exposed to 
methylphenidate can alter drug-rewarded behavior and enhance 
drug responsiveness in adulthood and suggests that treating 
young children (e.g. preschool age) with methylphenidate may 
increase the risk of drug addiction later in life. Our 
second hypothesis was not supported; early exposure to 
methylphenidate did not change the number of D2 receptors.
We had originally predicted that an increase in morphine-
induced CPP would also be associated with decreased levels
of D2 receptors, our negative finding has implications for 
the current understanding of morphine-induced reward in 
regards to the dopaminergic theory of addiction. In 
conclusion, the well known link between ADHD and subsequent 
substance abuse (Wilens, Biederman, Mick, Faraone, &
Spencer, 1997; Clure, Brady, Saladin, Johnson, Waid, & 
Rittenbury, 1999; Schubiner et al., 2000), coupled with the
53
relative dearth of controlled studies on the long-term
effects of methylphenidate in young subjects, is emerging as 
an important public health issue which requires further
study.
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